{"id":"ropinirole-immediate-release","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyskinesia"}]},"_chembl":{"chemblId":"CHEMBL1200411","moleculeType":"Small molecule","molecularWeight":"296.84"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This activation helps to increase the levels of dopamine in the brain, which can help to alleviate symptoms of Parkinson's disease. Ropinirole is a non-ergoline dopamine agonist, which means it does not have the same side effects as ergoline-based dopamine agonists.","oneSentence":"Ropinirole is a dopamine agonist that works by activating dopamine receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:37.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Parkinson's disease"},{"name":"Treatment of restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT03250117","phase":"PHASE1, PHASE2","title":"Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2017-10-10","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT03708237","phase":"PHASE2","title":"Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2019-02-19","conditions":"Restless Legs Syndrome, End Stage Renal Disease","enrollment":3},{"nctId":"NCT00256854","phase":"PHASE3","title":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-14","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":135},{"nctId":"NCT00996944","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-30","conditions":"Restless Legs Syndrome","enrollment":34},{"nctId":"NCT00140712","phase":"PHASE1","title":"Ropinirole Tablets In Young Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-10","conditions":"Restless Legs Syndrome","enrollment":9},{"nctId":"NCT00331149","phase":"PHASE3","title":"A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-20","conditions":"Parkinson Disease","enrollment":343},{"nctId":"NCT00314860","phase":"PHASE3","title":"RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":568},{"nctId":"NCT00144300","phase":"PHASE4","title":"Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-01","conditions":"Parkinson Disease","enrollment":246},{"nctId":"NCT00986245","phase":"PHASE4","title":"Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-09","conditions":"Parkinson Disease","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ropinirole prolonged release"],"phase":"phase_3","status":"active","brandName":"ropinirole immediate release","genericName":"ropinirole immediate release","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropinirole is a dopamine agonist that works by activating dopamine receptors in the brain. Used for Treatment of Parkinson's disease, Treatment of restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}